Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SNSE 
Sensei Biotherapeutics Inc (SNSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SNSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.61% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.17M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 2 | Beta 0.31 | 52 Weeks Range 5.00 - 18.35 | Updated Date 10/17/2025 |
52 Weeks Range 5.00 - 18.35 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.75% | Return on Equity (TTM) -67.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -14212874 | Price to Sales(TTM) - |
Enterprise Value -14212874 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 1261290 | Shares Floating 828302 |
Shares Outstanding 1261290 | Shares Floating 828302 | ||
Percent Insiders 34.14 | Percent Institutions 5.58 |
Upturn AI SWOT
Sensei Biotherapeutics Inc
Company Overview
History and Background
Sensei Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapies for cancer. Founded in 2011, the company is leveraging its ImmunoPhage platform to generate vaccines that target specific tumor antigens and stimulate an immune response. The company has primarily been focused on pre-clinical development and early-stage clinical trials.
Core Business Areas
- Immuno-oncology Drug Development: Sensei focuses on developing immunotherapeutic agents, particularly vaccines, designed to stimulate the body's immune system to fight cancer cells. Their main platform technology is ImmunoPhage.
Leadership and Structure
Sensei Biotherapeutics has a management team led by a CEO and other key executives overseeing research and development, clinical operations, and finance. Their organizational structure is typical of a biotechnology company, with departments focused on different aspects of drug development.
Top Products and Market Share
Key Offerings
- SES-001: SES-001 is preclinical. Data is unavailable at this time
- SNS-301: SNS-301 is Sensei's lead clinical program, a bacteriophage-based cancer vaccine targeting Asparagine Endopeptidase (AEP), which is overexpressed in multiple solid tumors. As of the last update, it was in Phase 1/2 clinical trials. Market share data isn't applicable at this development stage, and revenue is minimal. Competitors include companies developing cancer vaccines such as BioNTech (BNTX) and Moderna (MRNA) in personalized cancer therapies, and companies targeting solid tumor microenvironments.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, driven by the increasing prevalence of cancer and advances in understanding the immune system's role in fighting cancer. The market is characterized by intense competition, high R&D spending, and a strong focus on innovation.
Positioning
Sensei Biotherapeutics is positioned as an innovative company developing novel cancer immunotherapies using its ImmunoPhage platform. Its competitive advantage lies in the uniqueness of its technology, which aims to elicit a strong and targeted immune response against tumors.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. Sensei's positioning allows it to potentially capture a portion of this TAM, dependent on the success of its clinical trials and commercialization efforts.
Upturn SWOT Analysis
Strengths
- Novel ImmunoPhage platform
- Targeted cancer immunotherapy approach
- Experienced management team
- Strong preclinical data for lead candidate
Weaknesses
- Early-stage clinical development (high risk)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on a single platform technology
- Unproven commercialization capabilities
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new indications and targets
- Positive clinical trial results demonstrating efficacy
- Advancements in cancer immunology
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- CRSP
- LLY
Competitive Landscape
Sensei's ImmunoPhage platform is a unique approach but faces competition from established immuno-oncology therapies. Success hinges on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Sensei Biotherapeutics' historical growth has been limited, as the company is focused on R&D rather than generating revenue.
Future Projections: Future growth projections are heavily dependent on the success of its clinical trials and potential partnerships. Analyst estimates are subject to change based on clinical data and market conditions.
Recent Initiatives: Recent strategic initiatives include advancing SNS-301 through clinical trials and exploring new targets for its ImmunoPhage platform.
Summary
Sensei Biotherapeutics is an early-stage biotech company with a novel ImmunoPhage platform. Its success is dependent on clinical trial outcomes and securing partnerships. Key factors to watch include the progress of SNS-301 and any platform expansion. Financially, Sensei needs to carefully manage its cash flow. Competitors in the immuno-oncology space are intense, but the innovative angle could set them apart.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports, market research reports.
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensei Biotherapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Mr. John K. Celebi M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.senseibio.com |
Full time employees 14 | Website https://www.senseibio.com | ||
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.